Reports Q2 revenue $61.37M, consensus $55.45M. “I’m proud of our second quarter results, with 49% year-over-year revenue growth, strong margin improvements, and continued progress toward profitability,” said Sean Duffy, Co-founder and CEO of Omada Health (OMDA). “We believe our Q2 performance reflects Omada’s ability to capture tailwinds in cardiometabolic care, to effectively commercialize our GLP-1 Care Track, and to leverage advances in artificial intelligence for the benefit of our members.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health’s Strategic Partnerships and AI Leverage Drive Growth and Profitability Outlook
- Omada Health, Inc.: A Promising Buy Amid Technical Weakness and Growth Potential
- Goldman Sachs Beats the Drum on These 2 ‘Strong Buy’ Stocks
- Nike upgraded, Sportradar initiated: Wall Street’s top analyst calls
- Omada Health initiated with a Buy at Canaccord